- Dell Plans to Sell Computer Factories: Report
- Euro Zone Collateral Rules Toughen to Fight Abuse
- European Shares Set to Fall in Global Equity Selloff
- South Korea Intervenes Again to Help Falling Won
- Samsung Electronics Is Mulling SanDisk Options
- Lone Star May Sue S.Korea Government on KEB Deal
- Japan Capex Falls, Hitting GDP Amid Global Worries
- Sony Recalls Laptops on Burn Concern, Shares Tumble
- Asian Markets Get Hammered, Japan Sheds 2.8%
- Wells Fargo Responds to Bill Gross Comments
- Sell Block: Cramer Condemns Hovnanian
- Lightning Round OT: Corning, Giant Interactive and More
- Lightning Round: FedEx, Deere, Dow Chemical and More
- H&R Block Taxed for No Reason?
- Six Reasons to Stay Positive
- Your First Move For Friday September 5th
- Web Extra: Fast & Furious Friday Trades
- Beginning Of Tech Unwind?
Invitrogen plans to buy Applied Biosystems in a deal valued at $6.7 billion to form a massive provider of research tools for the life sciences industry, the companies said on Thursday.
The purchase price of $38 per share in cash and stock represents a premium of 17 percent over Applied Biosystems' closing price on Wednesday and 12 percent over its average closing price over the past 30 days. The split is expected to be 45 percent cash and 55 percent Invitrogen stock.
The combined company will generate about $3.5 billion in combined sales, offering a wide variety of products in areas such as genetic analysis, proteomics, cell biology and cell systems.
Applied Biosystems' equipment includes mass spectrometers, which can measure the molecular weight of proteins and thereby identify them.
Invitrogen [IVGN
Loading...
()
] shares fell 10 percent after the deal announcement, while Applied Biosystems [ABI
Loading...
()
] rose 8 percent.
"In the most general terms, it makes sense in terms of their expertise in molecular biology, efficiencies in combined sales forces, overlap on product line and intellectual property interests," said Deutsche Bank analyst Ross Muken. Such a combination was a source of speculation at a conference in Denver last week, he added.
Upon closing, Invitrogen shareholders would own the majority of the merged company, which would be named Applied Biosystems.
Applied Biosystems is one of two tracking stocks of Applera, which announced the deal with Invitrogen. Celera Group [CRA
Loading...
()
] is the other.
The companies expect the merger to close in the fall and to be neutral to or slightly help earnings per share in the first year and significantly positive in the second year.
Invitrogen shares fell $4.35 to $39 in early electronic trading from a Wednesday close of $43.35 on Nasdaq.
Applied Biosystems shares rose to $35 from Wednesday's New York Stock Exchange close of $32.44.




